<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew R Freedman, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Robertson, MRCP, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The human T-lymphotropic virus type I (HTLV-I) is a retrovirus that infects 10 to 20 million people worldwide, as estimated by seroprevalence studies. However, HTLV-I is associated with disease in only approximately 5 percent of infected individuals [<a href="#rid1">1,2</a>].</p><p>The diagnosis and treatment of HTLV-I infection and what is known about the disease associations will be reviewed here. The virology, pathogenesis, and epidemiology of HTLV-I are discussed separately. (See  <a class="medical medical_review" href="/d/html/8316.html" rel="external">"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DISEASE ASSOCIATIONS</span><span class="headingEndMark"> — </span>The majority of HTLV-I-infected individuals will remain asymptomatic, but there are two well-recognized disease associations caused by the virus:</p><p class="bulletIndent1"><span class="glyph">●</span>Adult T cell leukemia-lymphoma (ATL)</p><p class="bulletIndent1"><span class="glyph">●</span>HTLV-I-associated myelopathy (HAM), also known as tropical spastic paraparesis (TSP).</p><p></p><p>In addition, several other clinical entities have been described in infected patients  (<a class="graphic graphic_table graphicRef66919" href="/d/graphic/66919.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3"><span class="h2">Adult T cell leukemia-lymphoma</span><span class="headingEndMark"> — </span>HTLV-I was first isolated from a patient with a cutaneous T cell lymphoma in 1980 [<a href="#rid3">3</a>]. Since then it has become clear that the cumulative lifetime risk of ATL in a patient with HTLV-I infection is between 2 and 5 percent. The risk is slightly higher in males; the onset of ATL is typically delayed for 20 to 30 years after the viral infection [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"</a>.)</p><p>ATL is characterized by clonal proliferation of CD4+ T cells containing randomly integrated HTLV-I provirus, often associated with T cell receptor gene rearrangements. These cells have a distinct morphology with indented nuclei containing condensed chromatin and basophilic cytoplasm  (<a class="graphic graphic_picture graphicRef82314" href="/d/graphic/82314.html" rel="external">picture 1</a>). Four distinct clinical forms of ATL are recognized [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Acute</span><span class="headingEndMark"> — </span>Acute ATL accounts for 47 to 57 percent of cases and follows an aggressive course with a median survival of six months. Clinical features include: skin lesions (nodules, ulcers, generalized papular rash), lytic bone lesions, hypercalcemia, and pulmonary infiltrates. The latter may be due either to direct leukemic infiltration or to opportunistic infections such as <em>Pneumocystis jirovecii</em> (formerly <em>carinii</em>) pneumonia (PCP) resulting from acquired immunodeficiency syndrome (AIDS)-like immunodeficiency. Central nervous system (CNS) involvement occurs in up to 10 percent of cases. Laboratory findings include raised levels of lactate dehydrogenase and alkaline phosphatase as well as hypercalcemia.</p><p class="headingAnchor" id="H5"><span class="h3">Lymphomatous</span><span class="headingEndMark"> — </span>The lymphomatous form of ATL occurs in approximately 20 to 25 percent of cases. The clinical features include lymphadenopathy, hepatosplenomegaly, and skin lesions. Hypercalcemia is also common, but circulating tumor cells are unusual.</p><p class="headingAnchor" id="H6"><span class="h3">Chronic</span><span class="headingEndMark"> — </span>The chronic form, which accounts for 20 percent of cases, has a better prognosis with a median survival of approximately two years. Hypercalcemia does not occur, and there is no CNS or gastrointestinal involvement.</p><p class="headingAnchor" id="H7"><span class="h3">Smoldering</span><span class="headingEndMark"> — </span>Smoldering ATL is the least common type (approximately 5 percent of cases); median survival is more than five years. Skin and pulmonary lesions do occur, but other clinical features such as lymphadenopathy, hepatosplenomegaly, and hypercalcemia are absent. Less than 5 percent of peripheral CD4+ cells are involved, with proviral deoxyribonucleic acid (DNA) integrated in a monoclonal fashion.</p><p class="headingAnchor" id="H8"><span class="h3">Markers of disease progression</span><span class="headingEndMark"> — </span>Several serum markers have been found to be elevated, especially in the acute form of ATL. These include serum CD25 (interleukin-2 receptor), serum thymidine kinase activity, and serum neuron-specific enolase [<a href="#rid6">6-8</a>]. Investigators have proposed that CD25 and enolase, the levels of which are highly correlated, may serve as markers of disease progression and might be monitored during treatment. However, these tests are not currently used in clinical practice.</p><p class="headingAnchor" id="H9"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Use of standard regimens for advanced, aggressive non-Hodgkin lymphoma (NHL) is moderately effective, with most patients achieving initial partial or complete remission. However, early relapse is usual and median survival is only eight months.</p><p>A phase III trial comparing biweekly CHOP with a more aggressive chemotherapeutic regimen of VCAP (<a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) plus AMP (doxorubicin, ranimustine, and prednisone) plus VECP (<a class="drug drug_general" data-topicid="10303" href="/d/drug information/10303.html" rel="external">vindesine</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and prednisone) in 118 Japanese patients demonstrated significantly higher complete response rates with the more aggressive regimen (40 percent versus 25 percent, respectively) [<a href="#rid9">9</a>]. However, overall survival at three years was similar and toxicity-related morbidity and death was greater in the aggressive chemotherapy arm. Thus, the use of intensive combination chemotherapy remains investigational.</p><p>Allogeneic stem cell transplantation has been reported to benefit some patients already in remission [<a href="#rid10">10</a>]. </p><p>Chemotherapy for ATL is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">HTLV-I-associated myelopathy/tropical spastic paraparesis</span><span class="headingEndMark"> — </span>Although the first clinical description of TSP was published from the Caribbean in 1956 [<a href="#rid11">11</a>], it was not until 1985 that investigators reported the association of this condition with antibodies to HTLV-I in serum and cerebrospinal fluid (CSF) [<a href="#rid12">12,13</a>]. A group in Japan called the condition HAM in 1986 [<a href="#rid14">14</a>], but it was soon realized that TSP and HAM were the same entities.</p><p class="headingAnchor" id="H11"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>HAM/TSP is more common in females than males, in keeping with the higher prevalence of HTLV-I infection in females [<a href="#rid15">15-17</a>]. It affects less than 2 percent of HTLV-I carriers, with onset ranging from four months to 30 years (median 3.3 years) after infection [<a href="#rid15">15</a>]. In another prospective cohort analysis, HTLV-1-associated myelopathy was found in 3.7 percent (95% CI 1.4-8.0) and HTLV-II myelopathy in 1.0 percent (95% CI 0.3-2.5) [<a href="#rid16">16</a>]. </p><p>The risk factors for developing HAM/TSP are not well understood. One important risk factor appears to be a high provirus load [<a href="#rid18">18</a>]. In addition, certain polymorphisms in the interleukin (IL)-10 promoter and in the IL28B gene, which is involved in interferon lambda expression, may be associated with both provirus load and the risk of HAM/TSP [<a href="#rid19">19,20</a>]. </p><p>The illness is characterized by an insidious onset of slowly progressive weakness and spasticity of one or both legs, together with hyperreflexia, ankle clonus, extensor plantar responses, and lumbar pain [<a href="#rid21">21,22</a>]. Other features include back pain, detrusor instability leading to nocturia, urinary frequency, incontinence, and minor sensory changes, especially paresthesias and loss of vibration sense [<a href="#rid23">23</a>]. Cognitive function is unaffected and there is no upper limb involvement. </p><p>Individuals with HTLV-1 infection also appear to have an excess of neurological manifestations, even if they do not meet criteria for HAM/TSP. (See <a class="local">'Other neurological abnormalities'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Diagnostic criteria were agreed upon by a World Health Organization (WHO) panel in 1989  (<a class="graphic graphic_table graphicRef77037" href="/d/graphic/77037.html" rel="external">table 2</a>) [<a href="#rid24">24</a>]. In addition to the laboratory diagnostic tests listed in table 2, the use of HTLV-1 proviral load in the central nervous system (CNS) has been proposed as a new parameter for diagnosis of HAM/TSP [<a href="#rid25">25</a>].</p><p>Magnetic resonance imaging of the brain and spinal cord may be normal or may show atrophy of the cervical or thoracic cord and/or white matter lesions in the subcortical and periventricular regions [<a href="#rid26">26,27</a>]. Cerebrospinal fluid (CSF) examination reveals a low level lymphocytosis in approximately one-third of cases as well as a mildly elevated protein concentration [<a href="#rid28">28</a>]. Anti-HTLV-I antibodies are detectable in the CSF with a high CSF/serum ratio. Virus can be cultured from CSF lymphocytes and proviral DNA detected by PCR [<a href="#rid29">29</a>]. Neurophysiologic studies may reveal evidence of posterior column dysfunction as well as a peripheral neuropathy.</p><p class="headingAnchor" id="H13"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Management of HAM/TSP is primarily symptomatic, as disease-modifying treatment options are limited. A multidisciplinary International Retrovirology Association expert panel supports the use of systemic corticosteroids in patients with progressive disease (high-dose pulsed methyl <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> for induction; low-dose (5 mg) oral prednisolone for maintenance therapy) [<a href="#rid30">30</a>]. Systemic corticosteroids have been reported in some case series to slow progression [<a href="#rid31">31</a>], reduce neurologic disability [<a href="#rid32">32</a>], and improve pain [<a href="#rid33">33</a>], presumably through their anti-inflammatory effect [<a href="#rid34">34</a>]. However, other studies have reported no such benefit [<a href="#rid27">27,35</a>], and there have been no randomized clinical trials. </p><p>An anti-CCR4 monoclonal antibody, <a class="drug drug_general" data-topicid="118738" href="/d/drug information/118738.html" rel="external">mogamulizumab</a>, which has some efficacy in adult T cell leukemia and is available in Japan for that indication, may also have benefit in HAM/TSP. In a preliminary trial of 21 patients with HAM/TSP, varying doses of mogamulizumab were associated with improvements in spasticity and reductions in motor disability, as well as reductions in HTLV-I proviral load and markers of CNS inflammation [<a href="#rid36">36</a>]. Further study is warranted to define clinical efficacy, long-term safety, and optimal dosing of mogamulizumab for HAM/TSP. </p><p>Other agents with suggested benefit in small trials or observational studies include the anabolic steroid <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> [<a href="#rid37">37</a>] and interferon-beta1a [<a href="#rid38">38,39</a>]. </p><p>Antiviral therapy has not been shown to be effective in the treatment of HAM/TSP [<a href="#rid30">30</a>]. </p><p class="headingAnchor" id="H14"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>In a study of 123 patients with a 14-year follow-up, HAM/TSP was demonstrated to progress from disease onset to using a wheelchair over a median of 21 years [<a href="#rid40">40</a>].</p><p>A prospective cohort study [<a href="#rid16">16</a>], which included 160 patients with HTLV-I, revealed six cases of HAM/TSP diagnosed over a 12-year period (as well as a further four cases in 405 subjects with HTLV-II infection). Clinical progression was highly variable in this small cohort. The most severely affected subjects were using a wheelchair, while patients with mild cases only experienced difficulty rising from a chair.</p><p class="headingAnchor" id="H15"><span class="h2">Other disease manifestations</span></p><p class="headingAnchor" id="H16"><span class="h3">Other neurological abnormalities</span><span class="headingEndMark"> — </span>In addition to myelopathy, HTLV-1 infection is also associated with other neurological abnormalities, including isolated mild cognitive deficits, peripheral neuropathy, neurogenic bladder dysfunction, and amyotrophic lateral sclerosis [<a href="#rid41">41</a>]. In one study of 606 HTLV-1 infected individuals in Brazil, HTLV-1 proviral loads in patients with these neurologic manifestations were significantly higher than in asymptomatic carriers [<a href="#rid42">42</a>]. Another study found that HTLV-1 and HTLV-II infected patients were more likely than seronegative controls to have symptoms of leg weakness, impaired tandem gait, and urinary incontinence as well as physical examination findings of Babinski sign and impaired vibration sense [<a href="#rid43">43</a>]. </p><p>The frequency of neurologic signs and symptoms without definite HAM/TSP in HTLV-1-infected patients is uncertain. A study that included 251 HTLV-1-infected individuals in Brazil reported that over a maximum of eight years of follow-up, approximately 30 percent developed neurological manifestations without fulfilling the case definition for HAM/TSP [<a href="#rid44">44</a>]. However, these findings need to be interpreted with caution. No control group was used and self-reported symptoms to a team of neurologists, urologists, rheumatologists, psychologists, and dentists were used in determining the frequency of the neurological findings.</p><p class="headingAnchor" id="H17"><span class="h3">Infective dermatitis</span><span class="headingEndMark"> — </span>Infective dermatitis was first described in Jamaica in 1966 [<a href="#rid45">45</a>]. Subsequently, its association with HTLV-I infection was recognized in several endemic areas, including Japan and the Caribbean [<a href="#rid46">46,47</a>]. The onset is usually in early childhood, and the condition tends to improve with age. In a series of 42 cases from Brazil, the mean age of onset was 2.6 years (range 2 months to 11 years), with skin lesions appearing during the first year of life in about one-third of patients [<a href="#rid48">48</a>]. Remission occurred in 36 percent of cases, at a mean age of 15 years. </p><p>It is characterized by an eczematous, exudative rash affecting the scalp, postauricular region, face, axillae and groins. This may be associated with nasal involvement, including watery discharge and crusting of the anterior nares, and dermatopathic lymphadenopathy. Although the condition is caused primarily by HTLV-1 infection, secondary infection with Staphylococcus aureus or beta-hemolytic streptococci is common. Consequently, it usually responds well to antibiotics but tends to relapse upon stopping therapy.</p><p>In the Brazilian case series, almost one-half of the patients who had long-term follow-up were also ultimately diagnosed with HTLV-associated myelopathy/tropical spastic paraparesis [<a href="#rid48">48</a>]. (See <a class="local">'HTLV-I-associated myelopathy/tropical spastic paraparesis'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h3">Uveitis</span><span class="headingEndMark"> — </span>The association of HTLV-I infection with uveitis was first reported in Japan in 1989 [<a href="#rid49">49</a>]. It is more common in younger patients with HTLV-I (under the age of 50) and slightly more frequent in females, but its exact incidence among HTLV-I carriers remains uncertain. The condition presents with visual disturbance, including floaters and blurred or "foggy" vision, and is bilateral in nearly half of those affected [<a href="#rid50">50</a>]. Ocular signs include: iritis, vitreous opacities, retinal vasculitis and retinal hemorrhages and exudates. There is a good response to topical or systemic corticosteroids but relapse is common upon discontinuation of therapy.</p><p class="headingAnchor" id="H19"><span class="h3">Rheumatologic and pulmonary disorders</span><span class="headingEndMark"> — </span>A variety of rheumatologic conditions have been described in association with HTLV-I infection. A chronic inflammatory arthropathy has been reported in some patients, affecting predominantly the shoulders, wrists, and knees [<a href="#rid51">51</a>]. Synovial biopsy from involved joints reveals synovial cell proliferation together with lymphocytic infiltration [<a href="#rid51">51</a>].</p><p>Sjögren's disease has been described in a group of HTLV-I-infected patients with and without HAM/TSP [<a href="#rid52">52</a>]. Clinical features were similar to those seen in HTLV-I-negative Sjögren's disease and included dry eyes and mouth, ocular signs, and histologic evidence of glandular involvement. Some patients also had other autoimmune features such as arthropathy, Raynaud's, and interstitial pneumonitis.</p><p>Investigators in Jamaica reported HTLV-I positivity in 11 of 13 patients presenting with polymyositis and concluded that there was likely to be a causative relationship [<a href="#rid53">53</a>].</p><p>A lymphocytic alveolitis was first reported in 1987 in five Japanese patients with HAM/TSP [<a href="#rid54">54</a>]. Subsequent studies from Japan have also described radiographic and pathologic findings consistent with a lymphocytic bronchiolitis associated with HTLV-1 infection [<a href="#rid55">55-59</a>]. However, since these features may be found in asymptomatic patients, their clinical significance remains uncertain. </p><p>Aboriginal Australians have one of the highest prevalence rates of bronchiectasis in the world. One prospective study among aboriginal Australians found a very high seroprevalence of HTLV type 1 among hospitalized patients with bronchiectasis (nearly 60 percent) compared with historical background HTLV-1 prevalence rates (7 to 14 percent), suggesting that HTLV-1 infection may contribute to the risk of developing this pulmonary disease in this population [<a href="#rid60">60</a>]. </p><p>A high prevalence of bronchiectasis has also been reported in a UK cohort of HTLV-1 positive patients attending a national referral center [<a href="#rid61">61</a>]. Overall, 3.4 percent had bronchiectasis confirmed by high resolution chest CT, compared with a reported prevalence of 0.1 percent in the general population. The risk of bronchiectasis was higher among those with symptomatic HTLV-1 infection (ie, HAM/TSP, ATL, HTLV-associated inflammatory disease) compared with asymptomatic patients (relative risk 19.2).</p><p class="headingAnchor" id="H20"><span class="h3">Immune thrombocytopenia (ITP)</span><span class="headingEndMark"> — </span>HTLV-I infection was found in 17 (22.1 percent) of 77 Japanese patients with ITP [<a href="#rid62">62</a>]. Response to steroid treatment was poor and five patients required splenectomy.</p><p class="headingAnchor" id="H21"><span class="h3">Gastric cancer</span><span class="headingEndMark"> — </span>Some epidemiologic data suggest that the incidence of gastric cancer may be lower in patients with HTLV-1 infection. For example, the incidence of gastric cancer is lower in Kamigoto compared with Nagasaki, Japan; in contrast the rate of HTLV-1 positivity in Kamigoto is high (30 percent among age groups at risk for gastric cancer) compared with other areas in Japan [<a href="#rid63">63</a>]. Some reports have also noted a low prevalence of Helicobacter pylori infection among patients infected with HTLV-1 [<a href="#rid64">64</a>].</p><p>A retrospective cohort study was performed in 5686 patients aged &gt;40 years in Kamigoto to assess the relationship between serologic evidence of HTLV-1 infection, H. pylori infection, and the subsequent development of gastric cancer over a decade of follow-up [<a href="#rid63">63</a>]. HTLV-1 infection was associated with a reduced risk of H. pylori infection and a lower risk of gastric cancer (OR, 0.38; 95% CI, 0.21-0.70).</p><p class="headingAnchor" id="H22"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of HTLV-I infection is generally based upon serologic testing to detect antibodies to the virus. An enzyme-linked immunosorbent assay (ELISA) is the most frequently used screening test, using antigens prepared from whole virus lysate or by recombinant technology [<a href="#rid65">65</a>]. Particle agglutination is an alternative [<a href="#rid66">66</a>]. Western blotting (WB) is normally used for confirmatory testing, which requires detection of antibodies to both gag and env viral gene products. WB also distinguishes between infection with HTLV-I and the less pathogenic HTLV-II [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/8316.html" rel="external">"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology"</a>.)</p><p>Some individuals with a positive screening ELISA test may have an indeterminate Western blot test, with incomplete antibody reactivity to HTLV-I antigens. The clinical significance of this finding is unclear, but may reflect prior exposure, cross-reactivity to other infectious agents, or infection with a novel retrovirus [<a href="#rid68">68</a>].</p><p>Polymerase chain reaction (PCR)-based testing to detect proviral DNA in peripheral blood mononuclear cells is an alternative diagnostic test. This test will also differentiate HTLV-I from HTLV-II infection. Advantages of this type of analysis are its ability to provide quantitation of proviral load in the blood [<a href="#rid69">69</a>], and its applicability in detecting proviral DNA in tumor cells or other tissue samples [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H23"><span class="h1">ANTIVIRAL TREATMENT AND PREVENTION</span><span class="headingEndMark"> — </span>Treatment is <strong>not</strong> indicated for asymptomatic individuals, and management of such patients is confined to the early diagnosis of clinical manifestations and to the prevention of transmission to others. The latter includes avoidance of breastfeeding in endemic areas, screening of blood donors, as well as the promotion of safe sex and discouraging needle sharing [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/8316.html" rel="external">"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology"</a>.)</p><p>There have been only limited studies of specific antiretroviral therapy for HTLV-I infection [<a href="#rid72">72</a>]. As noted above, the combination of the nucleoside analogue reverse transcriptase inhibitor (NRTI) <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> (ZDV), with IFN-alfa, has been used with some benefit in patients with ATL [<a href="#rid73">73,74</a>]. However, it is unclear whether the ZDV activity relates to its antiviral effect or to direct cytotoxicity.</p><p>The data on <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (3TC), another NRTI, are mixed with some in vitro and in vivo benefits noted, despite an apparent absence of antiviral activity. In one study, 3TC inhibited long-term growth of HTLV-I-infected peripheral blood mononuclear cells despite a lack of antiviral activity at clinically relevant concentrations [<a href="#rid75">75</a>]. Another report demonstrated HTLV-I resistance in its reverse transcriptase to 3TC but not to four other NRTIs (ZDV, <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a> [ddI], <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> [d4T], and zalcitabine [ddC]) [<a href="#rid76">76</a>]. 3TC has been administered alone and in combination to a few HTLV-I-infected patients with mixed results.</p><p class="bulletIndent1"><span class="glyph">●</span>Two patients with HAM/TSP were treated with 3TC plus ZDV; one patient had a 2-log reduction in proviral load after three months, which was sustained, but she did not experience neurologic improvement [<a href="#rid77">77</a>]. The second patient had a 1-log increase in proviral load.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, double-blind, placebo-controlled study of six months combination therapy with 3TC and ZDV in 16 patients with HAM showed no significant differences in clinical parameters or proviral load between treatment and placebo [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A series of five patients with HAM/TSP who received 3TC alone documented an approximate 10-fold decline in HTLV-I DNA initially followed by fluctuations between baseline and the lowest point thereafter [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General</strong> – The human T-lymphotropic virus (HTLV-I) is a retrovirus, which infects 10 to 20 million people worldwide, but is associated with disease in only approximately 5 percent of individuals. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease associations </strong>–<strong> </strong>Two well-recognized disease associations are caused by the virus: Adult T cell leukemia-lymphoma (ATL) and HTLV-I-associated myelopathy (HAM), also known as tropical spastic paraparesis (TSP). (See <a class="local">'Disease associations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adult T cell leukemia-lymphoma </strong>–<strong> </strong>Four distinct clinical forms of ATL are recognized: acute, lymphomatous, chronic, and smoldering. These various forms of disease have varying presentations and prognosis. The most common clinical presentation is acute ATL, which has the poorest overall survival of approximately six months. Treatment of ATL is discussed elsewhere. (See <a class="local">'Adult T cell leukemia-lymphoma'</a> above and  <a class="medical medical_review" href="/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HTLV-I-associated myelopathy/tropical spastic paralysis</strong> – HTLV-I associated myelopathy/tropical spastic paraparesis is characterized by an insidious onset of slowly progressive weakness and spasticity of one or both legs, together with hyperreflexia, ankle clonus, extensor plantar responses, and lumbar pain. No therapy is of proven benefit in HAM/TSP, but corticosteroids may slow progression and reduce both disability and pain. (See <a class="local">'HTLV-I-associated myelopathy/tropical spastic paraparesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other disease manifestations </strong>–<strong> </strong>Other disease manifestations include neuropathy, infiltrative skin disorders, uveitis, and rheumatologic and pulmonary disorders. (See <a class="local">'Other disease manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of HTLV-I infection is generally based upon serologic testing with ELISA followed by a confirmatory Western blot test. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prevention </strong>–<strong> </strong>Treatment is not indicated for asymptomatic HTLV-1 infection. (See <a class="local">'Antiviral treatment and prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H1551043175"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David T Scadden, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990; 3:1096.</a></li><li><a class="nounderline abstract_t">Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995; 87:1009.</a></li><li><a class="nounderline abstract_t">Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415.</a></li><li><a class="nounderline abstract_t">Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989; 43:1061.</a></li><li><a class="nounderline abstract_t">Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79:428.</a></li><li><a class="nounderline abstract_t">Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994; 73:2753.</a></li><li><a class="nounderline abstract_t">Araki K, Harada K, Nakamoto K, et al. Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol 2000; 119:259.</a></li><li><a class="nounderline abstract_t">Fujiwara H, Arima N, Ohtsubo H, et al. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol 2002; 71:80.</a></li><li><a class="nounderline abstract_t">Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25:5458.</a></li><li><a class="nounderline abstract_t">Obama K, Tara M, Sao H, et al. Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia. Int J Hematol 1999; 69:203.</a></li><li><a class="nounderline abstract_t">CRUICKSHANK EK. A neuropathic syndrome of uncertain origin; review of 100 cases. West Indian Med J 1956; 5:147.</a></li><li><a class="nounderline abstract_t">Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407.</a></li><li><a class="nounderline abstract_t">Gessain A, Francis H, Sonan T, et al. HTLV-I and tropical spastic paraparesis in Africa. Lancet 1986; 2:698.</a></li><li><a class="nounderline abstract_t">Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031.</a></li><li><a class="nounderline abstract_t">Maloney EM, Cleghorn FR, Morgan OS, et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:167.</a></li><li><a class="nounderline abstract_t">Orland JR, Engstrom J, Fridey J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 2003; 61:1588.</a></li><li><a class="nounderline abstract_t">Varandas CMN, da Silva JLS, Primo JRL, et al. Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients. Clin Infect Dis 2018; 67:1427.</a></li><li><a class="nounderline abstract_t">Yoshida M, Osame M, Kawai H, et al. Increased replication of HTLV-I in HTLV-I-associated myelopathy. Ann Neurol 1989; 26:331.</a></li><li><a class="nounderline abstract_t">Sabouri AH, Saito M, Lloyd AL, et al. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004; 190:1279.</a></li><li><a class="nounderline abstract_t">Treviño A, Lopez M, Vispo E, et al. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 55:e1.</a></li><li><a class="nounderline abstract_t">Nakagawa M, Izumo S, Ijichi S, et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1:50.</a></li><li><a class="nounderline abstract_t">Gotuzzo E, Cabrera J, Deza L, et al. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis 2004; 39:939.</a></li><li><a class="nounderline abstract_t">Castro NM, Rodrigues W Jr, Freitas DM, et al. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology 2007; 69:813.</a></li><li><a class="nounderline abstract_t">WHO. Virus diseases: Human T lymphotropic virus type I, HTLV-I. Wkly Epidemiol Rec 1989; 64:382.</a></li><li><a class="nounderline abstract_t">Lezin A, Olindo S, Oliere S, et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis? J Infect Dis 2005; 191:1830.</a></li><li><a class="nounderline abstract_t">Melo A, Moura L, Rios S, et al. Magnetic resonance imaging in HTLV-I associated myelopathy. Arq Neuropsiquiatr 1993; 51:329.</a></li><li><a class="nounderline abstract_t">Kira J, Fujihara K, Itoyama Y, et al. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 1991; 106:41.</a></li><li><a class="nounderline abstract_t">Milagres AC, Jorge ML, Marchiori PE, Segurado AA. Human T cell lymphotropic virus type 1-associated myelopathy in São Paulo, Brazil. Epidemiologic and clinical features of a university hospital cohort. Neuroepidemiology 2002; 21:153.</a></li><li><a class="nounderline abstract_t">Takenouchi N, Yamano Y, Usuku K, et al. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003; 9:29.</a></li><li><a class="nounderline abstract_t">Araujo A, Bangham CRM, Casseb J, et al. Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019. Neurol Clin Pract 2021; 11:49.</a></li><li><a class="nounderline abstract_t">Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol 1996; 2:345.</a></li><li><a class="nounderline abstract_t">Croda MG, de Oliveira AC, Vergara MP, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci 2008; 269:133.</a></li><li><a class="nounderline abstract_t">Buell KG, Puri A, Demontis MA, et al. Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy. PLoS One 2016; 11:e0152557.</a></li><li><a class="nounderline abstract_t">Bangham CR, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers 2015; 1:15012.</a></li><li><a class="nounderline abstract_t">Araújo AQ, Afonso CR, Leite AC, Dultra SV. Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Arq Neuropsiquiatr 1993; 51:325.</a></li><li><a class="nounderline abstract_t">Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. N Engl J Med 2018; 378:529.</a></li><li><a class="nounderline abstract_t">Harrington WJ Jr, Sheremata WA, Snodgrass SR, et al. Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses 1991; 7:1031.</a></li><li><a class="nounderline abstract_t">Oh U, Yamano Y, Mora CA, et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005; 57:526.</a></li><li><a class="nounderline abstract_t">Arimura K, Nakagawa M, Izumo S, et al. Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. J Neurovirol 2007; 13:364.</a></li><li><a class="nounderline abstract_t">Olindo S, Cabre P, Lézin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 2006; 63:1560.</a></li><li><a class="nounderline abstract_t">Leite AC, Mendonça GA, Serpa MJ, et al. Neurological manifestations in HTLV-I-infected blood donors. J Neurol Sci 2003; 214:49.</a></li><li><a class="nounderline abstract_t">Silva MT, Harab RC, Leite AC, et al. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis 2007; 44:689.</a></li><li><a class="nounderline abstract_t">Biswas HH, Engstrom JW, Kaidarova Z, et al. Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy. Neurology 2009; 73:781.</a></li><li><a class="nounderline abstract_t">Tanajura D, Castro N, Oliveira P, et al. Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. Clin Infect Dis 2015; 61:49.</a></li><li><a class="nounderline abstract_t">Sweet RD. A pattern of eczema in Jamaica. Br J Dermatol 1966; 78:93.</a></li><li><a class="nounderline abstract_t">LaGrenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990; 336:1345.</a></li><li><a class="nounderline abstract_t">La Grenade L, Manns A, Fletcher V, et al. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol 1998; 134:439.</a></li><li><a class="nounderline abstract_t">de Oliveira Mde F, Fatal PL, Primo JR, et al. Infective dermatitis associated with human T-cell lymphotropic virus type 1: evaluation of 42 cases observed in Bahia, Brazil. Clin Infect Dis 2012; 54:1714.</a></li><li><a class="nounderline abstract_t">Ohba N, Matsumoto M, Sameshima M, et al. Ocular manifestations in patients infected with human T-lymphotropic virus type I. Jpn J Ophthalmol 1989; 33:1.</a></li><li><a class="nounderline abstract_t">Mochizuki M, Tajima K, Watanabe T, Yamaguchi K. Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol 1994; 78:149.</a></li><li><a class="nounderline abstract_t">Nishioka K, Maruyama I, Sato K, et al. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989; 1:441.</a></li><li><a class="nounderline abstract_t">Nakamura H, Eguchi K, Nakamura T, et al. High prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy. Ann Rheum Dis 1997; 56:167.</a></li><li><a class="nounderline abstract_t">Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989; 2:1184.</a></li><li><a class="nounderline abstract_t">Sugimoto M, Nakashima H, Watanabe S, et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987; 2:1220.</a></li><li><a class="nounderline abstract_t">Ono K, Shimamoto Y, Matsuzaki M, et al. Diffuse panbronchiolitis as a pulmonary complication in patients with adult T-cell leukemia. Am J Hematol 1989; 30:86.</a></li><li><a class="nounderline abstract_t">Kadota J, Mukae H, Fujii T, et al. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 2004; 125:1239.</a></li><li><a class="nounderline abstract_t">Fujii M, Sumi Y, Atarashi K, et al. Muscle weakness in extremities and diffuse centrilobular nodules in lungs. HTLV-1-associated bronchiolo-alveolar disorder. Thorax 2011; 66:546.</a></li><li><a class="nounderline abstract_t">Okada F, Ando Y, Yoshitake S, et al. Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1. Radiology 2006; 240:559.</a></li><li><a class="nounderline abstract_t">Yamashiro T, Kamiya H, Miyara T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol 2012; 19:952.</a></li><li><a class="nounderline abstract_t">Einsiedel L, Fernandes L, Spelman T, et al. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012; 54:43.</a></li><li><a class="nounderline abstract_t">Honarbakhsh S, Taylor GP. High prevalence of bronchiectasis is linked to HTLV-1-associated inflammatory disease. BMC Infect Dis 2015; 15:258.</a></li><li><a class="nounderline abstract_t">Matsushita K, Ozaki A, Arima N, Tei C. Human T-lymphotropic virus type I infection and idiopathic thrombocytopnic purpura. Hematology 2005; 10:95.</a></li><li><a class="nounderline abstract_t">Matsumoto S, Yamasaki K, Tsuji K, Shirahama S. Human T lymphotropic virus type 1 infection and gastric cancer development in Japan. J Infect Dis 2008; 198:10.</a></li><li><a class="nounderline abstract_t">Isomoto H, Mizuta Y, Fukushima K, et al. Low prevalence of Helicobacter pylori in individuals with HTLV-I infection. Eur J Gastroenterol Hepatol 1999; 11:497.</a></li><li><a class="nounderline abstract_t">Kline RL, Brothers T, Halsey N, et al. Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. Lancet 1991; 337:30.</a></li><li><a class="nounderline abstract_t">Ikeda M, Fujino R, Matsui T, et al. A new agglutination test for serum antibodies to adult T-cell leukemia virus. Gan 1984; 75:845.</a></li><li><a class="nounderline abstract_t">Wiktor SZ, Alexander SS, Shaw GM, et al. Distinguishing between HTLV-I and HTLV-II by western blot. Lancet 1990; 335:1533.</a></li><li><a class="nounderline abstract_t">Yao K, Hisada M, Maloney E, et al. Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I. J Infect Dis 2006; 193:427.</a></li><li><a class="nounderline abstract_t">Miley WJ, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses 2000; 16:665.</a></li><li><a class="nounderline abstract_t">Duggan DB, Ehrlich GD, Davey FP, et al. HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood 1988; 71:1027.</a></li><li><a class="nounderline abstract_t">Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group. Ann Intern Med 1993; 118:448.</a></li><li><a class="nounderline abstract_t">Macchi B, Balestrieri E, Mastino A. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro. J Antimicrob Chemother 2003; 51:1327.</a></li><li><a class="nounderline abstract_t">Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744.</a></li><li><a class="nounderline abstract_t">Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl 1:S186.</a></li><li><a class="nounderline abstract_t">Balestrieri E, Forte G, Matteucci C, et al. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother 2002; 46:3080.</a></li><li><a class="nounderline abstract_t">García-Lerma JG, Nidtha S, Heneine W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J Infect Dis 2001; 184:507.</a></li><li><a class="nounderline abstract_t">Machuca A, Rodés B, Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 2001; 78:93.</a></li><li><a class="nounderline abstract_t">Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006; 3:63.</a></li><li><a class="nounderline abstract_t">Taylor GP, Hall SE, Navarrete S, et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 1999; 73:10289.</a></li></ol></div><div id="topicVersionRevision">Topic 8317 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213510" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6261256" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2732000" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1751370" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8194016" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632660" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353304" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968021" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10222661" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13381082" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A neuropathic syndrome of uncertain origin; review of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2863442" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2876179" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : HTLV-I and tropical spastic paraparesis in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2871307" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : HTLV-I associated myelopathy, a new clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473019" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663047" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912303" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802532" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased replication of HTLV-I in HTLV-I-associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15346339" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460962" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222342" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472843" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482910" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Virus diseases: Human T lymphotropic virus type I, HTLV-I</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871115" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8297235" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Magnetic resonance imaging in HTLV-I associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1779238" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006779" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Human T cell lymphotropic virus type 1-associated myelopathy in São Paulo, Brazil. Epidemiologic and clinical features of a university hospital cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587066" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33968472" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912211" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258264" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27077747" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27188208" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HTLV-1-associated myelopathy/tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8297234" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414279" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1812944" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15786444" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17849320" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101824" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972388" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neurological manifestations in HTLV-I-infected blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278060" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738173" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820277" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5907441" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A pattern of eczema in Jamaica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1978165" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infective dermatitis of Jamaican children: a marker for HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554295" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467669" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infective dermatitis associated with human T-cell lymphotropic virus type 1: evaluation of 42 cases observed in Bahia, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2733251" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ocular manifestations in patients infected with human T-lymphotropic virus type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123625" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human T lymphotropic virus type 1 uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2563817" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chronic inflammatory arthropathy associated with HTLV-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135218" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572904" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : HTLV-1 and polymyositis in Jamaica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2890850" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : T-lymphocyte alveolitis in HTLV-I-associated myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643859" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diffuse panbronchiolitis as a pulmonary complication in patients with adult T-cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078730" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606478" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Muscle weakness in extremities and diffuse centrilobular nodules in lungs. HTLV-1-associated bronchiolo-alveolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864677" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578413" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095566" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143070" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High prevalence of bronchiectasis is linked to HTLV-1-associated inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019454" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Human T-lymphotropic virus type I infection and idiopathic thrombocytopnic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544011" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Human T lymphotropic virus type 1 infection and gastric cancer development in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755252" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Low prevalence of Helicobacter pylori in individuals with HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1670658" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6096197" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A new agglutination test for serum antibodies to adult T-cell leukemia virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1972466" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Distinguishing between HTLV-I and HTLV-II by western blot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16388491" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791877" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895676" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382459" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716774" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760890" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797722" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183277" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471110" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520583" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of antiretroviral therapy on HTLV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984654" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10559346" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
